411 related articles for article (PubMed ID: 34117234)
1. Plasma biomarkers of Alzheimer's disease improve prediction of cognitive decline in cognitively unimpaired elderly populations.
Cullen NC; Leuzy A; Janelidze S; Palmqvist S; Svenningsson AL; Stomrud E; Dage JL; Mattsson-Carlgren N; Hansson O
Nat Commun; 2021 Jun; 12(1):3555. PubMed ID: 34117234
[TBL] [Abstract][Full Text] [Related]
2. Combining plasma Aβ and p-tau217 improves detection of brain amyloid in non-demented elderly.
Niimi Y; Janelidze S; Sato K; Tomita N; Tsukamoto T; Kato T; Yoshiyama K; Kowa H; Iwata A; Ihara R; Suzuki K; Kasuga K; Ikeuchi T; Ishii K; Ito K; Nakamura A; Senda M; Day TA; Burnham SC; Iaccarino L; Pontecorvo MJ; Hansson O; Iwatsubo T
Alzheimers Res Ther; 2024 May; 16(1):115. PubMed ID: 38778353
[TBL] [Abstract][Full Text] [Related]
3. Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease.
Benedet AL; Leuzy A; Pascoal TA; Ashton NJ; Mathotaarachchi S; Savard M; Therriault J; Kang MS; Chamoun M; Schöll M; Zimmer ER; Gauthier S; Labbe A; Zetterberg H; Rosa-Neto P; Blennow K;
Brain; 2020 Dec; 143(12):3793-3804. PubMed ID: 33210117
[TBL] [Abstract][Full Text] [Related]
4. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
[TBL] [Abstract][Full Text] [Related]
5. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease.
Mattsson N; Cullen NC; Andreasson U; Zetterberg H; Blennow K
JAMA Neurol; 2019 Jul; 76(7):791-799. PubMed ID: 31009028
[TBL] [Abstract][Full Text] [Related]
6. Longitudinal plasma p-tau217 is increased in early stages of Alzheimer's disease.
Mattsson-Carlgren N; Janelidze S; Palmqvist S; Cullen N; Svenningsson AL; Strandberg O; Mengel D; Walsh DM; Stomrud E; Dage JL; Hansson O
Brain; 2020 Dec; 143(11):3234-3241. PubMed ID: 33068398
[TBL] [Abstract][Full Text] [Related]
7. Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers.
Mattsson-Carlgren N; Salvadó G; Ashton NJ; Tideman P; Stomrud E; Zetterberg H; Ossenkoppele R; Betthauser TJ; Cody KA; Jonaitis EM; Langhough R; Palmqvist S; Blennow K; Janelidze S; Johnson SC; Hansson O
JAMA Neurol; 2023 Apr; 80(4):360-369. PubMed ID: 36745413
[TBL] [Abstract][Full Text] [Related]
8. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
Leuzy A; Smith R; Cullen NC; Strandberg O; Vogel JW; Binette AP; Borroni E; Janelidze S; Ohlsson T; Jögi J; Ossenkoppele R; Palmqvist S; Mattsson-Carlgren N; Klein G; Stomrud E; Hansson O
JAMA Neurol; 2022 Feb; 79(2):149-158. PubMed ID: 34928318
[TBL] [Abstract][Full Text] [Related]
9. Prediction of future Alzheimer's disease dementia using plasma phospho-tau combined with other accessible measures.
Palmqvist S; Tideman P; Cullen N; Zetterberg H; Blennow K; ; Dage JL; Stomrud E; Janelidze S; Mattsson-Carlgren N; Hansson O
Nat Med; 2021 Jun; 27(6):1034-1042. PubMed ID: 34031605
[TBL] [Abstract][Full Text] [Related]
10. Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders.
Palmqvist S; Janelidze S; Quiroz YT; Zetterberg H; Lopera F; Stomrud E; Su Y; Chen Y; Serrano GE; Leuzy A; Mattsson-Carlgren N; Strandberg O; Smith R; Villegas A; Sepulveda-Falla D; Chai X; Proctor NK; Beach TG; Blennow K; Dage JL; Reiman EM; Hansson O
JAMA; 2020 Aug; 324(8):772-781. PubMed ID: 32722745
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease.
Moscoso A; Grothe MJ; Ashton NJ; Karikari TK; Lantero Rodríguez J; Snellman A; Suárez-Calvet M; Blennow K; Zetterberg H; Schöll M;
JAMA Neurol; 2021 Apr; 78(4):396-406. PubMed ID: 33427873
[TBL] [Abstract][Full Text] [Related]
12. The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease.
Simrén J; Leuzy A; Karikari TK; Hye A; Benedet AL; Lantero-Rodriguez J; Mattsson-Carlgren N; Schöll M; Mecocci P; Vellas B; Tsolaki M; Kloszewska I; Soininen H; Lovestone S; Aarsland D; ; Hansson O; Rosa-Neto P; Westman E; Blennow K; Zetterberg H; Ashton NJ
Alzheimers Dement; 2021 Jul; 17(7):1145-1156. PubMed ID: 33491853
[TBL] [Abstract][Full Text] [Related]
13. Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study.
de Wolf F; Ghanbari M; Licher S; McRae-McKee K; Gras L; Weverling GJ; Wermeling P; Sedaghat S; Ikram MK; Waziry R; Koudstaal W; Klap J; Kostense S; Hofman A; Anderson R; Goudsmit J; Ikram MA
Brain; 2020 Apr; 143(4):1220-1232. PubMed ID: 32206776
[TBL] [Abstract][Full Text] [Related]
14. Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias.
Alcolea D; Delaby C; Muñoz L; Torres S; Estellés T; Zhu N; Barroeta I; Carmona-Iragui M; Illán-Gala I; Santos-Santos MÁ; Altuna M; Sala I; Sánchez-Saudinós MB; Videla L; Valldeneu S; Subirana A; Pegueroles J; Hirtz C; Vialaret J; Lehmann S; Karikari TK; Ashton NJ; Blennow K; Zetterberg H; Belbin O; Blesa R; Clarimón J; Fortea J; Lleó A
J Neurol Neurosurg Psychiatry; 2021 Nov; 92(11):1206-1214. PubMed ID: 34103344
[TBL] [Abstract][Full Text] [Related]
15. Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma Aβ42/Aβ40 and p-tau.
Janelidze S; Palmqvist S; Leuzy A; Stomrud E; Verberk IMW; Zetterberg H; Ashton NJ; Pesini P; Sarasa L; Allué JA; Teunissen CE; Dage JL; Blennow K; Mattsson-Carlgren N; Hansson O
Alzheimers Dement; 2022 Feb; 18(2):283-293. PubMed ID: 34151519
[TBL] [Abstract][Full Text] [Related]
16. Combining plasma phospho-tau and accessible measures to evaluate progression to Alzheimer's dementia in mild cognitive impairment patients.
Pichet Binette A; Palmqvist S; Bali D; Farrar G; Buckley CJ; Wolk DA; Zetterberg H; Blennow K; Janelidze S; Hansson O
Alzheimers Res Ther; 2022 Mar; 14(1):46. PubMed ID: 35351181
[TBL] [Abstract][Full Text] [Related]
17. Mitigating the Associations of Kidney Dysfunction With Blood Biomarkers of Alzheimer Disease by Using Phosphorylated Tau to Total Tau Ratios.
Janelidze S; Barthélemy NR; He Y; Bateman RJ; Hansson O
JAMA Neurol; 2023 May; 80(5):516-522. PubMed ID: 36987840
[TBL] [Abstract][Full Text] [Related]
18. Plasma phosphorylated tau-217 exhibits sex-specific prognostication of cognitive decline and brain atrophy in cognitively unimpaired adults.
Saloner R; VandeVrede L; Asken BM; Paolillo EW; Gontrum EQ; Wolf A; Lario-Lago A; Milà-Alomà M; Triana-Baltzer G; Kolb HC; Dubal DB; Rabinovici GD; Miller BL; Boxer AL; Casaletto KB; Kramer JH
Alzheimers Dement; 2024 Jan; 20(1):376-387. PubMed ID: 37639492
[TBL] [Abstract][Full Text] [Related]
19. Sex differences in blood biomarkers and cognitive performance in individuals with autosomal dominant Alzheimer's disease.
Vila-Castelar C; Chen Y; Langella S; Lopera F; Zetterberg H; Hansson O; Dage JL; Janelidzde S; Su Y; Chen K; Pluim McDowell C; Martinez JE; Ramirez-Gomez L; Garcia G; Aguillon D; Baena A; Giraldo-Chica M; Protas HD; Ghisays V; Rios-Romenets S; Tariot PN; Blennow K; Reiman EM; Quiroz YT
Alzheimers Dement; 2023 Sep; 19(9):4127-4138. PubMed ID: 37279390
[TBL] [Abstract][Full Text] [Related]
20. Associations of Plasma Phospho-Tau217 Levels With Tau Positron Emission Tomography in Early Alzheimer Disease.
Janelidze S; Berron D; Smith R; Strandberg O; Proctor NK; Dage JL; Stomrud E; Palmqvist S; Mattsson-Carlgren N; Hansson O
JAMA Neurol; 2021 Feb; 78(2):149-156. PubMed ID: 33165506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
